BACKGROUND: The Australian Trial in Acute Hepatitis C (ATAHC) is a National Institutes of Health-funded prospective cohort study of the natural history and efficacy of treatment in individuals with recently acquired hepatitis C. Enrollment is open to both human immunodeficiency virus (HIV)-infected and -uninfected individuals. The aim of this article was to evaluate characteristics and virological outcomes among HIV-infected individuals enrolled in ATAHC. METHODS: Eligibility criteria included the first positive result of testing for anti-hepatitis C virus (HCV) antibody within 6 months and either clinical hepatitis diagnosed within the past 12 months or documented anti-HCV seroconversion within the past 24 months. RESULTS: Of the initial 103 patients enrolled, 27 (26%) were HIV infected. HIV-infected patients were more likely to be older, to have HCV genotype 1 infection and high levels of HCV RNA at baseline than were HCV-monoinfected patients. Sexual acquisition accounted for the majority (56%) of HCV infections among HIV-infected patients, compared with only 8% of HCV-monoinfected patients. The median duration from estimated HCV infection to treatment was 30 weeks. Treatment with 24 weeks of pegylated interferon and ribavirin resulted in rates of undetectability of HCV RNA of 95%, 90%, and 80% at weeks 12, 24, and 48, respectively. Undetectability at week 4 was achieved in 44% of patients and yielded positive and negative predictive values for sustained virological response of 100% and 33%, respectively. CONCLUSIONS: Significant differences were demonstrated between HIV-infected and HIV-uninfected individuals enrolled in ATAHC. Treatment responses among HIV-infected individuals with both acute and early chronic infection are encouraging and support regular HCV screening of high-risk individuals and early treatment for recently acquired HCV infection.
BACKGROUND: The Australian Trial in Acute Hepatitis C (ATAHC) is a National Institutes of Health-funded prospective cohort study of the natural history and efficacy of treatment in individuals with recently acquired hepatitis C. Enrollment is open to both human immunodeficiency virus (HIV)-infected and -uninfected individuals. The aim of this article was to evaluate characteristics and virological outcomes among HIV-infected individuals enrolled in ATAHC. METHODS: Eligibility criteria included the first positive result of testing for anti-hepatitis C virus (HCV) antibody within 6 months and either clinical hepatitis diagnosed within the past 12 months or documented anti-HCV seroconversion within the past 24 months. RESULTS: Of the initial 103 patients enrolled, 27 (26%) were HIV infected. HIV-infectedpatients were more likely to be older, to have HCV genotype 1 infection and high levels of HCV RNA at baseline than were HCV-monoinfected patients. Sexual acquisition accounted for the majority (56%) of HCV infections among HIV-infectedpatients, compared with only 8% of HCV-monoinfected patients. The median duration from estimated HCV infection to treatment was 30 weeks. Treatment with 24 weeks of pegylated interferon and ribavirin resulted in rates of undetectability of HCV RNA of 95%, 90%, and 80% at weeks 12, 24, and 48, respectively. Undetectability at week 4 was achieved in 44% of patients and yielded positive and negative predictive values for sustained virological response of 100% and 33%, respectively. CONCLUSIONS: Significant differences were demonstrated between HIV-infected and HIV-uninfected individuals enrolled in ATAHC. Treatment responses among HIV-infected individuals with both acute and early chronic infection are encouraging and support regular HCV screening of high-risk individuals and early treatment for recently acquired HCV infection.
Authors: E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht Journal: Hepatology Date: 2003-09 Impact factor: 17.425
Authors: J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: J Ghosn; S Pierre-François; V Thibault; C Duvivier; R Tubiana; A Simon; M A Valantin; S Dominguez; E Caumes; C Katlama Journal: HIV Med Date: 2004-07 Impact factor: 3.180
Authors: Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Monica C Robotin; Joy Copland; Graham Tallis; David Coleman; Carolien Giele; Louise Carter; Jenean Spencer; John M Kaldor; Gregory J Dore Journal: J Gastroenterol Hepatol Date: 2004-03 Impact factor: 4.029
Authors: Lynn E Taylor; Marisa Holubar; Kunling Wu; Ronald J Bosch; David L Wyles; John A Davis; Kenneth H Mayer; Kenneth E Sherman; Karen T Tashima Journal: Clin Infect Dis Date: 2011-01-31 Impact factor: 9.079
Authors: Christoph Boesecke; Patrick Ingiliz; Thomas Reiberger; Hans-Jürgen Stellbrink; Sanjay Bhagani; Emma Page; Stefan Mauss; Thomas Lutz; Esther Voigt; Marguerite Guiguet; Marc-Antoine Valantin; Axel Baumgarten; Mark Nelson; Martin Vogel; Jürgen K Rockstroh Journal: Infection Date: 2016-02 Impact factor: 3.553
Authors: Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2014 Impact factor: 2.471
Authors: Gregory J Dore; Margaret Hellard; Gail V Matthews; Jason Grebely; Paul S Haber; Kathy Petoumenos; Barbara Yeung; Philippa Marks; Ingrid van Beek; Geoffrey McCaughan; Peter White; Rosemary French; William Rawlinson; Andrew R Lloyd; John M Kaldor Journal: Gastroenterology Date: 2009-09-24 Impact factor: 22.682
Authors: E Orsetti; S Staffolani; R Gesuita; G De Iaco; E Marchionni; L Brescini; P Castelli; F Barchiesi Journal: Infection Date: 2013-05-24 Impact factor: 3.553